For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Nootropic / Cognitive

Dihexa

Also known as: PNB-0408

Dihexa (PNB-0408) is a small-molecule hexapeptide-like analog of angiotensin IV developed at Washington State University by the Harding/Wright group as a preclinical candidate for Alzheimer's disease and cognitive decline. It is NOT FDA-approved and has never been tested in human clinical trials. The often-quoted claim that it is 'roughly ten million times more potent than BDNF' refers to EC50 comparisons in an in vitro dendritic spine assay, not clinical efficacy.

Where to buy · live market data

Who's worth your money for Dihexa

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

🇺🇸 Glacier Aminos 99

Highest Merit Score (99) of 9 scored sellers

$14.00/mg

$69.99 · 5mg

1 COA
Buy Code MERIT · 10% off

Best value

🇺🇸 Moglabs 98

Lowest $/mg among scored sellers

$0.27/mg

$40.00 · 150mg · 99.6% purity

2 COAs
Buy

Most tested

🇺🇸 Licensed Peptides 95

2 independent COAs on file

$13.00/mg

$130 · 10mg

2 COAs
Buy Code MERIT · 5% off

Average price

$9.68/mg

Sellers

23

45-day trend

-25.4%

14 of 23 sellers have a current price· 5 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Dihexa

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Dihexa

CAS

1401708-83-5

Molecular formula

C27H44N4O5

Typical dose range

2-5 mg/day subcutaneous or 10-40 mg/day oral/intranasal; typical research cycles 4-6 weeks on with 2-4 weeks off

Half-life

12.68 days (i.v., rat); 8.83 days (i.p., rat); ~2-4 hours estimated for oral/intranasal routes

Independent evidence

COAs for Dihexa

12 third-party tests across 7 vendors. Each card links to the full report.

All 12 COAs for Dihexa →
Measured purity 99.5%–99.9% across 4 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.46 %
Mar 2026
Chromate Moderate

For

Dihexa

by Moglabs· batch DIH001

✓ Vendor-published
99.57 %
Mar 2026
MogLabs.bio

For

Dihexa

by Moglabs· batch DIH001

COA on file
✓ Vendor-published
99.57 %
Mar 2026
Chromate Moderate

For

Dihexa

by Ruo Bio· batch DIH001

COA on file
Aggregated · 3rd-party listing
99.90 %
Apr 2025
BioRegen Moderate · HPLC

For

Dihexa

by BioLongevity Labs· batch cmojb7lwg01cqkirxjd6royw0

Aggregated · 3rd-party listing
97.83 %
MZ Biolabs Moderate

For

Dihexa

by Kimera Chems· batch KC-DHX-02

Aggregated · 3rd-party listing
—
Sep 2026

Purity not on file

Ethos Analytics Strong

For

Dihexa

by Glacier Aminos· batch DICAPGA-01

Aggregated · 3rd-party listing
—
May 2026

Purity not on file

Ethos Analytics Strong

For

Dihexa

by Licensed Peptides· batch 26126001

✓ Vendor-published
—
May 2026

Purity not on file

Ethos Analytics Strong

For

Dihexa

by Licensed Peptides· batch 26126001

COA on file
Aggregated · 3rd-party listing
—
May 2025

Purity not on file

MZ Biolabs Moderate

For

Dihexa

by Genetic Peptide· batch A22250127

Aggregated · 3rd-party listing
—
Mar 2025

Purity not on file

Janoshik Analytical Limited

For

Dihexa

by Skye Peptides· batch 01DXA25

✓ Vendor-published
—

Purity not on file

Lab unknown

For

DIHEXA

by Moglabs

COA on file
✓ Vendor-published
—

Purity not on file

Lab unknown

For

Dihexa

by Ruo Bio

COA on file
Research depth

12 citations indexed for Dihexa

All research on Dihexa →

review · 2026

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.

animal · 2026

Umbilical cord mesenchymal stromal cells-derived HGF inhibits STING-mediated pyroptosis to alleviate cerebral ischemia/reperfusion injury via c-Met/β-catenin/RNF5 pathway

BACKGROUND: Pyroptosis plays an essential role in the pathological process of cerebral ischemia/reperfusion (I/R) injury. Hepatocyte growth factor (HGF)-modified stem cells improve brain I/R damage.

Study · 2025

Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury

Mild traumatic brain injury (mTBI) can produce persistent cognitive and behavioral deficits. These impairments result in a reduced quality of life and difficulty returning to work, school, or other activities.

in-vitro · 2025

Comparative analysis of small molecule and growth factor-derived human induced pluripotent stem cell-derived hepatocyte-like cells

The growth factor and small molecule protocol are the two primary approaches for generating human induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-HLCs). We compared the efficacy of the growth factor and small molecule protocols across fifteen different human iPSC lines.

animal · 2025

Generation and applications of an expandable and mature hiPSC-derived liver organoid

Organoids have emerged as a powerful tool for modeling liver diseases, drug screening, and personalized treatments. However, they have a limited capacity to generate functional hepatocytes in a reproducible and efficient manner.

animal · 2024

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats

Background Huntington's disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric dysfunction caused by a mutant huntingtin protein.